During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD ...

在最新一期的Blood Advances中，Soumerai等研究者发布了慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的专家共识治疗指南，这是淋巴瘤研究基金会（LRF）首次召集专家小组制定的系统性内容，标志着治疗领域的重要里程碑。

但 65 岁以上患者对 FCR 耐受性较差，可采用苯达莫司汀联合利妥昔单抗（BR）或苯丁酸氮芥联合 CD20 单克隆抗体等替代方案。 近年来，靶向治疗成为 CLL/SLL 治疗的研究热点。维奈克拉（Venetoclax）是一种新型靶向治疗药物，2016 年获美国食品药品监督管理局（FDA ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

“The preclinical data suggest that it is more active than rituximab in cells that have a low number of CD20 molecules on the surface, which is characteristic of CLL but probably less important ...

Lead programs include CD20-targeting CAR T cells for non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), being developed in collaboration with Fred Hutchinson Cancer Research Center ...

CD52 is found on CLL cells and many T lymphocytes. CD20 is found on B lymphocytes, which are the cells where CLL starts. You typically get monoclonal antibodies by infusion into a vein.

Venetoclax-based regimens and second-generation cBTKis offer superior long-term disease control in CLL compared to older ... (VenO), 17.4% received anti-CD20 monotherapy, and 7.4% received ...

In early clinical trials, small-molecule inhibitors of the B-cell signal transduction have demonstrated improvement in response rates in elderly patients with CLL, suggesting that they may become ...